18F-FDG PET/CT in detecting immune-related adverse events
10.3760/cma.j.cn321828-20200827-00326
- VernacularTitle:18F-FDG PET/CT监测免疫相关不良反应的临床应用
- Author:
Jingnan WANG
1
;
Xuezhu WANG
;
Xu YANG
;
Haitao ZHAO
;
Li ZHANG
;
Yingyi WANG
;
Fang LI
;
Li HUO
Author Information
1. 中国医学科学院、北京协和医学院北京协和医院核医学科、核医学分子靶向诊疗北京市重点实验室，北京 100730
- Keywords:
Immune-related adverse events;
Immune checkpoint inhibitors;
Positron-emission tomography;
Tomography, X-ray computed;
Fluorodeoxyglucose F18;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(2):118-121
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) have shown significant efficacy in clinical trials and applications of various malignant tumors, and have been approved for clinical application in China. ICIs can cause immune-related adverse events (irAEs), which may affect any organs. Early identification and appropriate treatment can improve patient outcome. 18F-FDG PET/CT is capable of early detection of irAEs and provides effective clinical guidance. This article reviews the clinical application of 18F-FDG PET/CT in detecting irAEs, including typical imaging findings and research progress.
